Physician profile
Shailesh Malla
NPI 1437154267
$4,750.84
in general payments reported to CMS, 2019-2025
24 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $676 · 2021: $699 · 2022: $528 · 2023: $776 · 2024: $750 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $983.62 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $831.41 | 2019-2025 | |
| Amgen INC. | $667.95 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $372.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $286.72 | 2019-2025 | |
| Amarin Pharma, INC. | $243.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $242.00 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $210.04 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $201.71 | 2020-2025 | Nexletol |
| Edwards Lifesciences Corporation | $164.90 | 2019-2025 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $141.16 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $73.59 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $44.05 | 2024 | Arcalyst |
| Boston Scientific Corporation | $36.64 | 2025 | Cds - Mct/Cem Monitoring |
| Abbott Laboratories | $32.55 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $31.39 | 2024 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $31.04 | 2020 | |
| Gilead Sciences, INC. | $29.78 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.83 | 2023 | Lifevest |
| Arbor Pharmaceuticals, INC. | $28.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.45 | 2023 | Jardiance |
| Heartflow, INC. | $16.88 | 2022 | |
| Medtronic, INC. | $14.00 | 2024 | Venaseal |
| Scpharmaceuticals INC. | $13.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailesh Malla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.